Business Overview: Cypherpunk Technologies Inc. (NASDAQ: CYPH)

---

Executive Summary

Cypherpunk Technologies Inc. is a Delaware corporation originally incorporated on January 3, 2011 as Leap Therapeutics, Inc., a clinical-stage oncology company headquartered in Cambridge, Massachusetts. On November 12, 2025, the company renamed itself Cypherpunk Technologies and changed its ticker from LPTX to CYPH after pivoting its corporate capital-allocation strategy toward a digital-asset treasury built on Zcash (ZEC), a privacy-focused cryptocurrency, while retaining its legacy antibody-drug clinical programs inside a subsidiary, Leap Therapeutics, Inc.

The company today is best understood as two businesses bolted together: (1) a Zcash-accumulation treasury vehicle, seeded by a roughly $58.9 million private placement led by Winklevoss Capital in October 2025, modeled on the "Bitcoin treasury company" playbook popularized by firms such as Strategy Inc. (MicroStrategy); and (2) a small, pre-revenue biomarker-targeted antibody oncology pipeline (lead candidate sirexatamab/DKN-01) that predates the pivot and continues to run in parallel.

Cypherpunk matters as an early, high-profile example of the "altcoin treasury company" trend extending beyond Bitcoin and Ethereum into a privacy-coin niche, with a legacy clinical-stage biotech asset riding along as a largely separate, smaller-scale program.

---

1. Core Business Model & How They Work

Cypherpunk's primary current business model does not generate operating revenue in the traditional sense. Instead, it raises capital (equity/private placements) and deploys it to accumulate ZEC, aiming to compound shareholder value through appreciation in the underlying asset and the company's claimed share of Zcash's fixed circulating supply — directly analogous to a Bitcoin treasury company, but for a privacy-focused coin.

 Equity/private       ➡️   Capital deployed to    ➡️   ZEC held on balance      ➡️  Shareholder value tied to
 placement raises          accumulate ZEC               sheet (treasury              ZEC price + % of
 (e.g., $58.9M Winklevoss   (open-market purchases,      asset; target: ≥5%           circulating supply held
 Capital-led round,         also $5M into ZODL, the      of circulating supply)
 Oct. 2025)                 post-ECC Zcash dev co.)
                                                                 ⬆
                                             Separate, pre-existing legacy track:
                                             Leap Therapeutics subsidiary runs
                                             sirexatamab (DKN-01) oncology trials,
                                             funded from the same corporate entity

As of March 11, 2026, the company reported holding 294,743.10 ZEC at an average purchase price of $335.89, equal to roughly 1.76% of Zcash's circulating supply, with a stated (and explicitly revisable) goal of accumulating at least 5% of supply over time. A subsequent purchase round brought holdings to approximately 290,062–350,000+ ZEC range as reported in press coverage, funded with further capital raises; ZEC's price has been volatile, falling from roughly $650 in November 2025 to the $500s by early 2026, with CYPH shares falling roughly 60% over a similar window.

---

2. Business Segments

                    Cypherpunk Technologies Inc.
                                |
          -----------------------------------------
          |                                         |
  Digital Asset Treasury                   Clinical-Stage Oncology
  ("Cypherpunk" parent strategy)           (Leap Therapeutics, Inc. subsidiary)
          |                                         |
  - ZEC accumulation (~294,743 ZEC            - Sirexatamab (DKN-01):
    as of 3/11/2026, target ≥5%                 Phase 2 DeFianCe study in
    of circulating supply)                       2L MSS colorectal cancer
  - $58.9M Winklevoss Capital-led              - FL-501: preclinical GDF-15
    private placement (Oct. 2025)                antibody program
  - $5M investment in ZODL (Zcash
    dev. company, post-ECC, Mar. 2026)

The two businesses are not comparable on a revenue basis — the treasury segment holds a large, price-volatile crypto asset but produces no operating revenue, while the oncology subsidiary is pre-revenue and clinical-stage — so no revenue-share split is presented. Capital commitment is heavily weighted toward the treasury strategy: the ~$58.9 million raised for ZEC accumulation dwarfs the resources being applied to the legacy oncology programs, and the company's post-pivot identity, name, and ticker are now built around the treasury business.

---

3. Product Portfolio / Pipeline

---

4. Competitive Landscape

Treasury/capital-markets competition: Zcash exchange-traded products (e.g., Grayscale Zcash Trust), Bitcoin itself as the dominant treasury-asset alternative, other publicly traded digital-asset treasury companies (e.g., Strategy Inc.), cryptocurrency miners, and crypto-native venture firms such as a16z crypto — all of which compete for the same pool of investor capital seeking crypto balance-sheet exposure. Cypherpunk's positioning is narrower and more speculative than Bitcoin-centric peers: it is betting on a privacy-coin thesis specifically, which is a smaller and more regulator-sensitive niche than Bitcoin treasury strategies.

Oncology competition: Multiple large, well-capitalized developers are active in the anti-DKK1 antibody space, including Novartis, Merck, Amgen, Pfizer, and Junshi Biosciences, alongside broader platform/tools competitors cited in the company's own filing. Leap's oncology program is a small, under-resourced effort relative to these competitors' balance sheets.

                 High regulatory/clinical risk
                           ^
                           |
              Sirexatamab (DKN-01) *
              FL-501 (preclinical) *
                           |
  Niche/narrow   <---------+---------> Broad/mainstream
  asset thesis             |            asset thesis
  (privacy coin)           |
              ZEC treasury *            Bitcoin treasury cos.
                           |             (e.g., Strategy Inc.)
                           v
                 Low regulatory/clinical risk

---

5. Strategic Strengths & Risks

Strengths / moat sources:

• High-profile, well-capitalized backer (Winklevoss Capital) lent early credibility and a large initial capital base ($58.9 million) relative to the company's prior size.
• First-mover positioning in a Zcash-specific treasury strategy, a narrow niche most other digital-asset treasury companies have not targeted.
• Legacy clinical IP optionality: the Leap Therapeutics oncology assets retain some underlying value/optionality independent of the crypto strategy, even though they are not currently the market's focus.

Risks:

• Extreme asset-price volatility and concentration. The company's primary value driver is the spot price of a single cryptocurrency; ZEC fell roughly 15–20% over a few months in the period reviewed, and CYPH shares fell roughly 60% over a similar window.
• Regulatory risk specific to privacy coins. Privacy-enhancing cryptocurrencies face elevated scrutiny from regulators and have previously faced exchange delistings in some jurisdictions — a risk not shared by more mainstream treasury assets like Bitcoin.
• Dilution. The treasury strategy depends on repeated capital raises to keep accumulating ZEC, which dilutes existing shareholders.
• Dual-business complexity and capital-allocation conflict. Running an unrelated clinical-stage oncology program alongside a crypto-treasury strategy creates governance and resource-allocation complexity, and risks management attention being split.
• Small organization. The company reported only 6 full-time employees as of December 31, 2025 — a very thin operating base for managing both a large crypto treasury and an active Phase 2 oncology program.
• No demonstrated statistically significant efficacy yet for the lead oncology asset (PFS benefit not statistically significant in DeFianCe).

---

6. Financial Overview

---

7. Summary Conclusion

Cypherpunk Technologies is not a traditional operating business with a conventional moat; it is a capital-markets vehicle whose value is tied almost entirely to the price of Zcash and to how much of the coin's circulating supply it can accumulate before competitors or market conditions change. Its only real differentiation is being an early, well-capitalized, high-profile entrant into the privacy-coin treasury niche, layered awkwardly on top of a legacy, pre-revenue oncology pipeline it has not divested. The dominant forward risk is straightforward: a sustained decline in ZEC's price, tightening privacy-coin regulation, or an inability to keep raising dilutive capital would directly and immediately impair the company's primary asset, while the oncology program remains a separate, under-resourced, binary-outcome bet riding alongside it.